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Abstract 
BACKGROUND: Wells syndrome is a rare idiopathic dermatosis of the eosinophilic spectrum. Diagnostic criteria 
include cutaneous eruptions of variable morphology with eosinophilic infiltrates, peripheral blood eosinophilia, a 
relapsing, remitting course, and exclusion of systemic disease. Diagnosis is often delayed.  
CASE PRESENTATION: We present a 28-year older man with recently developed pruritic and sometimes painful 
erythema. His medical history was positive for coughing in the evening that started in November 2012. Later, a 
pansinusitis developed. Early diagnosis improves the outcome.  
CONCLUSION: Standardized treatment has yet to be developed. In our case, systemic corticosteroids were of 
limited value only. 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
Eosinophilic skin diseases are characterised 
by eosinophil infiltration and/or degranulation in skin 
lesions, with or without blood eosinophilia. Eosinophils 
can defend against microbes, to regulate 
inflammation, cause tissue damage, promote 
remodelling and fibrosis, and initiate pruritus. Tissue 
eosinophilia can be caused by cytokine-mediated 
increased differentiation and survival of eosinophils 
(extrinsic eosinophilic disorders), and mutation-
mediated clonal expansion of eosinophils (intrinsic 
eosinophilic disorders). Increased generation of 
interleukin (IL)-5 producing T-lymphocytes is often 
involved [1]. 
Eosinophilic skin diseases are 
heterogeneous. Pruritus is a common symptom. 
These disorders can be classified in:  
- allergy-related (allergic drug eruption, 
urticaria, allergic contact dermatitis, atopic dermatitis), 
- parasitic infestations and arthropod bites,  
- infection-related (chronic pulmonary 
aspergillosis, HIV, Toxocara canis), 
- autoimmune blistering (bullous pemphigoid, 
dermatitis herpetiformis), and 
- those of unknown origin (idiopathic).  
The latter group, which is extremely 
heterogeneous and rare, includes Wells syndrome 
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(eosinophilic cellulitis), granuloma faciale, eosinophilic 
pustular folliculitis, recurrent cutaneous eosinophilic 
vasculitis, Job syndrome, angiolymphoid hyperplasia 
with eosinophilia, and eosinophilic fasciitis [2]. Here 
we present a case of Wells syndrome with a 
remarkable delay of diagnosis. 
 
 
Case Report 
 
A 28-year older man presented with recently 
developed pruritic and sometimes painful erythema 
(Figure 1). His medical history was positive for 
coughing in the evening that started in November 
2012. In January 2018, he contacted his GP because 
of fever. He got a prescription for codeine and oral 
antibiotic. 
  
Figure 1: Clinical presentation of Wells syndrome (eosinophilic 
cellulitis) with large erythematous and brownish macules with 
slightly elevated borders: abdominal (left);  axillary (right) 
 
Because of a feeling of pressure and fullness 
of the paranasal sinuses, he went to an ENT 
specialist. The allergy tests remained negative, and 
he got a prescription for 200 mg-cineole capsules. 
In April 2018 he experienced a short breath in 
addition to coughing and greenish sputum. The 
pulmonologist diagnosed infection-triggered asthma. 
A corticoid asthma spray improved coughing 
temporarily. 
He presented himself again to the ENT 
specialist in July 2018 because of persistent coughing 
and nasal speech. He got a prescription for an oral 
antibiotic, prednisolone tablets and a corticoid-
containing nasal-spray. In August 2018 he suffered an 
allergic shock after novaminsulfon intake. A 
respiratory insufficiency was treated in the intensive 
care unit. Oral prednisolone medication was 
continued. A computerised tomography (CT) of 
paranasal sinuses demonstrated a massive polypoid 
pansinusitis with congestion of the cavities. At this 
point, the erythematous skin lesions appeared. 
On examination, we observed larger 
erythematous to brownish macules with a slightly 
elevated border of the armpits, peri- and infra-
umbilical, on fingers and thighs. There was no scaling, 
no blistering (Figure 1). 
A diagnostic skin biopsy revealed eosinophilic 
and neutrophilic infiltrate with dominance of 
eosinophils of the whole corium with presence of so-
called flame figures, i.e. degranulated eosinophils 
around collagen fibres.  
Eosinophilia of the cutis is suggestive of the 
following three differential diagnoses: Wells syndrome 
(Eosinophilic cellulitis - EC), Churg-Strauss syndrome 
(Eosinophilic granulomatosis with polyangiitis - 
EGPA), and hyper-eosinophilic syndrome (HES).  
Imaging: Echocardiography remained 
unremarkable. Dual X-ray energy of the chest was 
suggestive of atypical pneumonia treated with oral 
clindamycin (Figure 2). 
 
Figure 2: Chest X-ray with atypical pneumonia-like features 
 
Body plethysmography excluded obstructive 
or restrictive ventilation conditions. There was no hint 
for a diffusion abnormality either.  
Abdominal ultrasound demonstrated no 
pathological findings.  
The ENT council confirmed a chronic 
pansinusitis with an indication for functional 
endoscopic sinus surgery. Histology of the surgical 
specimen did not show tissue eosinophilia. After 
surgery, prednisolone was omitted. The exanthema 
re-appeared but was less severe. Dyspnea continued. 
Laboratory investigation: Eosinophil blood 
count 23.7 % (normal range: 0.8 – 7.0) or 2.03 G/L 
(0.04 – 0.54), total IgE 416.0 kU/L (< 100), 
lymphopenia of 20.0 % (25-45), creatine kinase 3.74 
µmol/s * L (0.00-2.90), total protein 62.4 g/L (66-87), 
25-OH-vitamine D 15.5 ng/L (20.0-80.0), C-reactive 
protein, ANA, c-ANCA, p-ANCA, myeloperoxidase, C3 
and C4 complement, antibodies to SSA/Ro, SSB/La, 
Scl-70, Jo-1, Sm, and RNP70 were normal or 
negative. 
In summary of our findings, we confirmed the 
diagnosis of Wells syndrome.  
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The medication at the end of hospital stay 
consisted of the following medical drugs: Cetirizine 10 
mg/d, methyl-prednisolone 8 mg/d, cortisone nasal 
spray; tiotropium bromide pulmonary spray and 
salmeterol xinafoate/fluticasone spray, cholecalciferol 
20.000 I.U. on day 1 and 15 of each month, and 
fluocinolone acetonide ointment for a maximum of 4 
weeks.  
 
 
Discussion 
 
Our patient underwent an odyssey to the final 
diagnosis of EC. Eventually, EGPA could be excluded 
by the normal finding of chest X-ray, body 
plethysmography, absence of tissue eosinophilia in 
surgical specimen from pansinusitis surgery, and 
absence of ANCA in peripheral blood. In skin 
histology there was no vasculitis, granulomas were 
missing [3]. 
HES has been recently redefined as: (1) 
Blood eosinophilia of greater than 1500/mm
3
 on at 
least two occasions or evidence of prominent tissue 
eosinophilia associated with symptoms and marked 
blood eosinophilia. (2) Exclusion of secondary causes 
of eosinophilia, such as parasitic or viral infections, 
allergic diseases, drug-induced or chemical-induced 
eosinophilia, hypoadrenalism, and neoplasms [4].  
EC or Wells syndrome was described in 1971 
by G. C. Wells as recurrent granulomatous dermatitis 
with eosinophilia [5]. EC has a sudden onset. During 
the course of the disease, patients present with 
recurrent episodes of acute pruritic dermatitis and / or 
painful edematous swellings or persistent urticarial 
eruptions. This was a leading symptom in the present 
patient.  
Table 1: Diagnostic criteria for eosinophilic cellulitis (Wells 
syndrome) 
Major criteria (2 of 4 required) 
Any of the previously reported clinical variants 
Plaque-type 
Annular-granuloma-like 
Urticaria-like 
Papulovesicular 
Bullous 
Papulonodular 
Fixed-Drug Eruption-like 
Relapsing, remitting course 
No systemic evidence disease 
Histology: eosinophilic infiltrates, no vasculitis 
Minor (at least 1 required) 
Histology: Flame figures 
Histology: Granulomatous change 
Laboratory: Peripheral eosinophilia not persistent and not greater than > 1500/μl 
Triggering factor (e.g. drug) 
 
Histopathology is useful in diagnostics. The 
findings vary with the disease stage, of course. 
Initially, oedema and a dermal infiltrate of eosinophils 
are seen. The sub-acute stage, as in our patient, is 
characterised by fibrinoid flame-figures of mid to deep 
dermis. Later on, eosinophils tend to disappear and 
are replaced by histiocytic granulomas. The absence 
of vasculitis is an important negative sign [6]. 
Diagnostic criteria have been proposed by 
Heelan et al., in 2013 [7] (Table 1).  
The cause of the disease is unknown, but 
other disorders may be associated with EC such as 
infections or hematologic disorders or medical drugs. 
Cases of EC arising in patients receiving biologics are 
increasingly reported [8], [9]. 
Systemic corticosteroids are usually helpful in 
EC, but the response may vary about associated 
pathologies. In our case, the previous corticosteroid 
treatments were too short, or the dosage was 
insufficient, leading to recurrences. Standard doses 
are 1 mg prednisolone per kg body weight. 
Sometimes higher dosages and repeated course are 
necessary. Cyclosporin A has been used at doses 
between 100 and 200 mg/d. Alternatives to systemic 
corticosteroids are dapsone with a dosage of up to 
200 mg/d if there is no glucose-6-phosphate 
dehydrogenase deficiency, antihistamines (with 
limited success), colchicine, chloroquine, and 
azathioprine among others. The combination of 
prednisolone 50 to 10 mg/d with dapsone 50 mg/d 
seems to induce a more rapid response. Randomised 
controlled trials are missing [10]. 
New treatment modalities are on the horizon. 
Case reports on successful treatment of EC with 
monoclonal anti-IgE antibody omalizumab have been 
published [11]. Increased expression of IL-5 has been 
reported in several cases. Therefore, antibodies 
directed against IL-5 (e.g. mepolizumab), IL-5-
receptor, and Siglec-8 could be a choice. Reduction of 
tissue eosinophilia can be achieved by 
dexpramipexole, tyrosine kinase inhibitors, Janus 
kinase inhibitors, or cytokine inhibitors to IL-13, IL-31, 
and others [12]. 
In conclusion, EC or Wells syndrome is a rare 
disorder of the spectrum of eosinophilic skin diseases. 
Diagnosis may be significantly delayed if this rare 
syndrome is not considered during a chronic relapsing 
course of variable complaints. Other eosinophilic 
disorders need to be excluded. Underlying or 
associated diseases of autoimmune, infectious or 
malignant nature need careful consideration. 
Treatment of choice is systemic corticosteroids, but 
more specific treatment options are on the horizon. 
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